Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 280

1.

Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.

Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD.

Cell Cycle. 2011 Sep 1;10(17):2959-66. Epub 2011 Sep 1.

PMID:
21862872
2.

The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.

Lyu H, Yang XH, Edgerton SM, Thor AD, Wu X, He Z, Liu B.

Oncotarget. 2016 Jan 19;7(3):2921-35. doi: 10.18632/oncotarget.6404.

3.

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.

Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee CK, Liu B.

Breast Cancer Res. 2013;15(5):R101.

4.

HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.

Huang X, Wang S, Lee CK, Yang X, Liu B.

Cancer Lett. 2011 Aug 1;307(1):72-79. doi: 10.1016/j.canlet.2011.03.019. Epub 2011 Apr 16.

PMID:
21497990
5.

Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.

Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.

Mol Pharmacol. 2006 Nov;70(5):1534-41. Epub 2006 Aug 3.

PMID:
16887935
6.

The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.

Huang J, Wang S, Lyu H, Cai B, Yang X, Wang J, Liu B.

Mol Cancer. 2013 Nov 11;12(1):134. doi: 10.1186/1476-4598-12-134.

7.

Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.

Zhao Y, Wang Z, Jiang Y, Yang C.

Cancer Lett. 2011 Dec 26;313(1):54-63. doi: 10.1016/j.canlet.2011.08.023. Epub 2011 Sep 3.

PMID:
21943825
9.

Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer.

Dokmanovic M, Hirsch DS, Shen Y, Wu WJ.

Mol Cancer Ther. 2009 Jun;8(6):1557-69. doi: 10.1158/1535-7163.MCT-09-0140. Epub 2009 Jun 9.

10.

Trastuzumab regulates IGFBP-2 and IGFBP-3 to mediate growth inhibition: implications for the development of predictive biomarkers for trastuzumab resistance.

Dokmanovic M, Shen Y, Bonacci TM, Hirsch DS, Wu WJ.

Mol Cancer Ther. 2011 Jun;10(6):917-28. doi: 10.1158/1535-7163.MCT-10-0980. Epub 2011 Apr 12.

11.

FOXO1A is a target for HER2-overexpressing breast tumors.

Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV.

Cancer Res. 2010 Jul 1;70(13):5475-85. doi: 10.1158/0008-5472.CAN-10-0176. Epub 2010 Jun 15.

12.

Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin.

Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ, Liu B.

Cancer Res. 2010 Feb 1;70(3):1204-14. doi: 10.1158/0008-5472.CAN-09-3321. Epub 2010 Jan 26.

13.

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.

Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ.

Cancer Res. 2005 Dec 1;65(23):11118-28. Erratum in: Cancer Res. 2008 Nov 15;68(22):9566.

14.

Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.

García-García C, Ibrahim YH, Serra V, Calvo MT, Guzmán M, Grueso J, Aura C, Pérez J, Jessen K, Liu Y, Rommel C, Tabernero J, Baselga J, Scaltriti M.

Clin Cancer Res. 2012 May 1;18(9):2603-12. doi: 10.1158/1078-0432.CCR-11-2750. Epub 2012 Mar 8.

15.

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M.

J Natl Cancer Inst. 2001 Dec 19;93(24):1852-7.

PMID:
11752009
16.

In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.

Ozbay T, Durden DL, Liu T, O'Regan RM, Nahta R.

Cancer Chemother Pharmacol. 2010 Mar;65(4):697-706. doi: 10.1007/s00280-009-1075-9. Epub 2009 Jul 28.

17.

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.

Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H.

Ann Oncol. 2010 Feb;21(2):255-62. doi: 10.1093/annonc/mdp304. Epub 2009 Jul 24.

PMID:
19633047
18.

Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.

Dayyani F, Parikh NU, Varkaris AS, Song JH, Moorthy S, Chatterji T, Maity SN, Wolfe AR, Carboni JM, Gottardis MM, Logothetis CJ, Gallick GE.

PLoS One. 2012;7(12):e51189. doi: 10.1371/journal.pone.0051189. Epub 2012 Dec 26.

19.

Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.

Zhang C, Duan X, Xu L, Ye J, Zhao J, Liu Y.

Breast Cancer Res Treat. 2012 Dec;136(3):739-48. doi: 10.1007/s10549-012-2316-x. Epub 2012 Nov 2.

PMID:
23117856
20.

Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.

Zsebik B, Citri A, Isola J, Yarden Y, Szöllosi J, Vereb G.

Immunol Lett. 2006 Apr 15;104(1-2):146-55. Epub 2005 Dec 12.

PMID:
16384610

Supplemental Content

Support Center